Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study
- 1 July 2009
- journal article
- clinical trial
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 148 (1) , 59-65.e1
- https://doi.org/10.1016/j.ajo.2009.02.006
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2006
- INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- Ranibizumab for Treatment of Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Neovascular Age-Related Macular DegenerationOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Bevacizumab in the treatment of colorectal cancerExpert Opinion on Biological Therapy, 2005
- Targeting angiogenesis, the underlying disorder in neovascular age-related macular degenerationCanadian Journal of Ophthalmology, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005